Result of AGM

RNS Number : 7744K

Immupharma PLC

27 June 2014

 

FOR IMMEDIATE RELEASE                                                                           27 JUNE 2014

ANNUAL GENERAL MEETING: 2014

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed. A summary of proxy votes is shown in the table below. Please also refer to the 'Notice of Meeting' in the Report & Accounts - 31 December 2013 (page 56).

RESOLUTION	FOR	%	AGAINST	%	WITHHELD
1*	42,555,134	97.12	1,260,750	2.88	141,750
2	43,294,291	98.59	620,750	1.41	276,450
3	37,577,751	85.31	6,472,290	14.69	141,450
4	43,655,791	99.10	394,250	0.90	141,450
5	43,402,829	98.53	645,750	1.47	142,912
6 (Special Resolution)	43,392,429	98.51	657,612	1.49	141,450

*A poll was requested at the AGM and completed. The resolution was passed. All other resolutions were passed by a show of hands.

As part of the formal proceedings Dimitri Dimitriou Chief Executive Officer made the following statement:

It is important to focus on the progress ImmuPharma has made over the last financial period and the embedded value of the assets.  There have been many achievements in 2013, including the grant by the FDA of a new and more attractive agreed protocol for our phase III trial of Lupuzor, the appointment of a very prestigious Scientific Advisory Board for Lupuzor with some of the leading Lupus opinion leaders in the US and Europe and the £50m facility from Darwin.  Our Nucant cancer phase I/IIa trial will be reporting results soon.  In addition, we recently announced that we have been granted new patents surrounding an "optically pure" version of ImmuPharma's Nucant family which broadens our usage into other indications.  Furthermore, through our collaboration with the CNRS, and announced only this morning, ImmuPharma has provided further details on its access to pioneering research in the Bordeaux region of France centred around novel peptide drugs through the University of Bordeaux and the Institut Européen de Chimie et Biologie (IECB).

Our key focus remains the progress of our lead compound Lupuzor into Phase III and we hope to provide an update in the near future.

The Board would like to thank its shareholders for their continued support as well as its scientific advisors and the CNRS for their long standing collaboration."

For further information please see the Group's web site, www.immupharma.com, or contact:

ImmuPharma PLC	[phone]
Richard Warr, Chairman
Dimitri Dimitriou, Chief Executive Officer Tracy Weimar, VP Operations and Finance
Lisa Baderoon, Head of Investor Relations	[phone]
Panmure Gordon	[phone]
Hugh Morgan, Fred Walsh, Duncan Monteith

 

END

 

 

RAGGMGZVZNLGDZM